A minor pathway for the biotransformation of morphine to hydromorphone has been identified in humans. Recently, an unsubstantiated claim that morphine is metabolized to hydromorphone and then to oxymorphone was published. The goal of this study was to determine if credible evidence that oxymorphone is a metabolite of either morphine or hydromorphone exists. Urine specimens from pain patients who were treated exclusively with high daily doses of morphine (N --34) or hydromorphone (N = 26) were analyzed by liquid chromatography-tandem mass spectrometry for oxymorphone, hydromorphone, and morphine (LOD = 25 ng/mL). Specimens were also tested for a variety of other medications. Criteria for inclusion of patients' specimens were as follows: 1. patients were undergoing exclusive dosing with either morphine or hydromorphone; 2. non-prescribed medications were not detected; and 3. urine concentrations of morphine were > 100,000 ng/mL for the high-dose morphine group and > 1000 ng/mL of hydromorphone for the high-dose hydromorphone group. Consistent with earlier reports, hydromorphone was detected in patients treated with high-dose morphine. The ratio of hydromorphone to morphine ranged from 0.2 to 2.2%. Oxymorphone was not detected in any specimen from high-dose morphine or high-dose hydromorphone patients. The authors conclude, based on these data, that oxymorphone is not a metabolite of morphine or hydromorphone.
Introduction
When a drug enters the human body, it is exposed to a variety of oxidative, reductive, hydrolytic, and conjugative enzymes. This plethora of human drug metabolizing enzymes may alter the drug's chemical structure in a variety of ways leading to the production of multiple metabolites. The parent drug may be partially or totally metabolized prior to elimination. Urinary excretion patterns of most therapeutic drugs have been studied, but new metabolites are occasionally discovered after market introduction. Minor metabolites, being in low concentrations and accounting for very little of the administered dose, may be completely overlooked. Discovery of these "minor metabolites" is often facilitated when the opportunity arises to study patients undergoing high-close therapy on a chronic regimen.
The opportunity to study pain patients undergoing highdose morphine or codeine therapy recently led to the discovery of new metabolites for both drugs. Morphine was shown to be metabolized to hydromorphone (1) and codeine to hydrocodone (2) . Both metabolites were excreted in urine in very low concentration relative to the parent drugs. Although these minor metabolites are not likely to have pharmacological significance, they are nevertheless important for different reasons. Both hydromorphone and hydrocodone have potent analgesic and antitussive properties and are available commercially in a variety of different commercial formulations. Both compounds also have significant abuse liability and their distribution is controlled by drug enforcement agencies throughout the world.
Prior to the discovery that hydromorphone and hydrocodone could be produced by metabolism of morphine and codeine, respectively, a positive urine test for these drugs, even in the presence of high concentrations of morphine or codeine, was interpreted as unauthorized use (unless independently prescribed by a physician). In some cases, punitive actions may have been taken. Following the discovery of these minor metabolites, the appropriate interpretation of positive tests for low concentrations of hydromorphone or hydrocodone, when accompanied by high concentrations of morphine or codeine, is that the results are consistent with morphine or codeine use.
An unsubstantiated claim of another minor metabolite of morphine was reported recently (3). This report stated that oxymorphone, "in rare instances", could be produced from morphine via secondary metabolism of hydromorphone. Unfortunately, no evidence was presented to document the claim of a new metabolic pathway leading from morphine to hydromorphone to oxymorphone (3) . This unsubstantiated claim has generated confusion for Medical Review Officers and health specialists involved in interpretation of urine drug tests. If such a metabolic pathway existed, then a positive urine test for oxymorphone at low concentration and accompanied by a high morphine concentration could be consistent with morphine administration. This is counter to the current state of knowledge of opiate metabolic pathways. It is known that oxycodone is partially metabolized to oxymorphone, which is excreted in urine as free and conjugated oxymorphone (4) . Oxymorphone administration also leads to excretion of free and conjugated oxymorphone (4), along with small amounts of other metabolites (5). However, no evidence is known by the current authors that a metabolic pathway exists for the production of oxymorphone from either morphine or hydromorphone.
The goal of the current study was to evaluate if metabolic pathways for the conversion of morphine or hydromorphone to oxymorphone exist. Urine specimens obtained from pain patients undergoing exclusive high-dose morphine or hydromorphone therapy were tested for the presence of oxymorphone. To avoid misinterpretation of results, criteria were included to eliminate non-compliant patients whose tests revealed use of nonprescribed medications (other than hydromorphone and/or oxymorphone) or illicit drug use. The working hypothesis in this study was that the presence of oxymorphone in urine in either or both of these two populations of pain patients undergoing highdose therapy would be suggestive evidence that this new metabolic pathway might exist (although non-prescribed use of oxymorphone or oxycodone would also explain the result and additional controlled dosing studies would be necessary to further resolve these issues). A negative finding for oxymorphone in both populations would be strong evidence that no such metabolic pathway exists for the conversion of morphine or hydromorphone to oxymorphone. All specimens meeting selection criteria were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS-MS) for oxymorphone, hydromorphone, morphine, other medications, and illicit drugs.
Experimental

Patients and specimens
Urine test records of chronic pain patients undergoing daily high-dose morphine or hydromorphone therapy were selected from a laboratory database (Aegis Sciences, PainComp TM program, Nashville, TN) for evaluation. All patients provided informed consent to allow urine drug monitoring. No additional tests were performed on any specimen. Results had been previously reported to the treating physician. After collation of records, patient confidentiality was protected by coding all records and the link to original records was destroyed. The specimens were collected and analyzed over the period of April 2007 to September 2007. Specimens for the high-dose morphine group were selected based on the following criteria: 1. patients were undergoing exclusive dosing with morphine for chronic pain under the care of a prescribing physician; 2. nonprescribed medications were not detected (with the exception of hydromorphone and/or oxymorphone); and 3. urine concentrations of morphine were in excess of 100,000 ng/mL. A similar set of criteria were used for selection of specimens for the highdose hydromorphone group; however, because of the higher potency of hydromorphone relative to morphine, a lower criteria for urine concentrations of hydromorphone was employed (i.e., > 1000 ng/mL). A total of 34 specimens met criteria for patients undergoing exclusive morphine therapy. These specimens were obtained from 15 different pain treatment clinics in 8 states (FL, TN, AL, KY, WV, TX, AZ, NC). Of the 34 high-dose morphine patients, 13 were male with an average age (SEM, range) of 52.9 (2.0, 33-62) years, and 21 were female with an average age of 52.0 (1.7, 40-61) years. A total of 26 specimens met criteria for patients undergoing high-dose hydromorphone therapy. These specimens were obtained from 12 different pain treatment clinics in 7 states (FL, TN, AL, KY, WV, AR, NC). Of the 26 high-dose hydromorphone patients, 11 were mate with an average age (SEM, range) of 52.2 (4.3, 27-74) years, and 15 were female with an average age of 49.4 (3.8, 26--80) years.
Urine analysis
Urine specimens were collected from all pain patients during regular office visits. Specimens were sealed and shipped to the laboratory for screening and confirmation analysis. Screening was performed for 13 classes of drugs (amphetamines, barbiturates, benzodiazepines, cannabis, carisoprodol, cocaine, meperidine, ecstasy, fentanyl, methadone, opiates, oxycodone, and propoxyphene). The assays were conducted with either Cedia | (Microgenics, Fremont, CA) or ELISA (Immunalysis, Pomona, CA) immunoassays according to manufacturers' procedures.
Specimens that screened positive were confirmed by LC-MS-MS for each drug class. A Shimadzu LC-20AD (Shimadzu Scientific Instruments, Columbia, MD) coupled to an API 3200 triple-quadrupole mass spectrometer (MS-MS) (Applied Biosystems, Foster City, CA) operating in positive electrospray mode (ESI) was used for analysis. Analytes were separated using a Restek Ultra Aqueous C18 (50 mm x 2.1 mm, 3 IJm). The flow rate was 0.5 mUmin, and the injection volume was 10 1JL. Solvent A consisted of 0.1% formic acid HPLC water; solvent B was 0.1% formic acid acetonitrile. Mobile phase composition ramped from 2% B to 10% B over 1 min, then increased to 25% B at 2.8 rain. The MS was operated in multiple reaction monitoring (MRM) mode. The precursor and product ions for each analyte and the internal standard were determined by direct infusion of pure compounds to the MS-MS compartment. The accuracy and precision of the assay was determined using urine matrix control material purchased from Quality Assurance Service (QASC, Athens, GA). Precursor/product ions (mass-to-charge ratio) were as follows: Deuterated internal standards were utilized for all analytes except dihydrocodeine. Related precursor and product ions were monitored. Hydrolysis of opiates was performed prior to confirmation analysis (5000 units of ~-glucuronidase, 3 h at 60~ Sigma, St. Louis, MO). The client reporting limit was 100 ng/mL for codeine, morphine, dihydrocodeine, hy-drocodone, hydromorphone, oxycodone, and oxymorphone. Additional criteria for reporting a positive result included the following: relative retention time _+ 0.006 compared to corresponding deuterated internal standard; • 20% ion ratios; and • 20% target control concentrations. The limit of quantitation (LOQ) and detection (LOD) for each analyte was determined by serial dilution of known drug concentrations. The LOQ was determined as the lowest concentration of drug/metabolite that satisfied all reporting criteria and could be accurately measured within • 20% of the target concentrations. The LOD was determined as the lowest concentration of drug/metabolite that satisfied all reporting criteria but was not accurately measured within _+ 20% of the target concentrations. The LOQs and LODs for the opiate drug/metabolites were determined to be 50 and 25 ng/mL, respectively. The upper limit of linearity (ULOL) of the assay for opiates was 15,000 ng/mL. All specimens exceeding the ULOL were serially diluted to concentrations within the LOL range. Percent coefficients of variation for the low control (187 ng/mL, n = 10) ranged from 1.7 to 10.4% and for high controls (375 ng/mL, n = 10) ranged from 2.2 to 7.7%.
All chromatograms of specimens from the patients undergoing high-dose morphine and hydromorphone therapy were reviewed for evidence of drug or metabolite content (oxymorphone, hydromorphone, codeine, hydrocodone) at concentrations below the reporting limits (100 ng/mL). The following categories were utilized to describe the results of this chromatographic review: 1. > LOQ, drug/metabolite concentrations were > LOQ, met all reporting criteria, and quantitative results were recorded; 2. > LOD, drug/metabolite concentrations were < LOQ but met ion ratio and retention time criteria; 3. signal-to-noise (S/N) > 3, chromatographic response was present at the appropriate retention time with a S/N > 3, but failed ion ratio criteria; and 4. not detected (ND), no chromatographic response (S/N < 3) was present at the appropriate retention time.
Results and Discussion
The patients in this study were administered either morphine or hydromorphone on a daily basis, were compliant in taking their prescribed medication (as evidenced by negative tests for other classes of drugs), and were not currently using illicit drugs. The mean (range) concentration of total morphine in urine for the 34 patients undergoing highdose morphine therapy was 205,015 (103,000-537,000) ng/mL (Table I) . For the high-dose hydromorphone group (N = 26), the mean (range) concentration of total hydromorphone was 3944 (1020-10,800) ng/mL (Table  II) .
The question of whether oxymorphone is a minor metabolite of morphine was addressed by a careful review of all chromatographic data related to the analysis of specimens obtained from both patient groups (high-dose morphine and high-dose hydromorphone). Chromatograms for the high-dose morphine * Abbreviations: ND, not detected, no chromatographic response (S/N < 3) was present at the appropriate retention time; S/N, signal to noise; S/N > 3, chromatographic response was present at the appropriate retention time with a S/N > 3 but failed ion ratio criteria; > LOD, drug/metabolite concentrations were < LOQ but met ion ratio and retention time criteria; and NA, not applicable.
group revealed no evidence for the presence of oxymorphone. No responses > LOD were recorded for oxymorphone and only one chromatogram contained a signal with S/N > 3 at the appropriate retention time (Table I , Patient #15). During chromatographic review, it was noted that the LC-MS-MS software occasionally identified a peak that emulated the ion ratios of oxymorphone and exhibited a retention time that was similar to that of the target analyte. Relative retention time calculations in comparison to the deuterium-labeled analogue internal standard were critical in excluding such peaks from misidentification as oxymorphone. Without due diligence, laboratory personnel could mistake such signals as oxymorphone. Review of chromatograms for the high-dose hydromorphone group also revealed no evidence for the presence of oxymorphone (Table II) . No responses were recorded for oxymorphone > LOD. The complete lack of detection of oxymorphone in specimens from patients undergoing daily morphine or hydromorphone treatment indicates that oxymorphone is not a metabolite 2  1050  ND  ND  3  1060  ND  ND  4  1060  ND  ND  5  1390  ND  ND  6  1420  ND  ND  7  1770  ND  ND  8  1910  ND  ND  9  2060  ND  ND  10  2390  ND  ND  11  2470  ND  ND  12  2520  ND  ND  13  2840  ND  ND  14  2860  ND  ND  15  3750  ND  ND  16  3860  ND  ND  17  4180  ND  ND  18  5270  ND  ND  19  5450  ND  ND  20  6200  ND  ND  21  6520  ND  ND  22  6670  ND  S/N > 3  23  7010  ND  ND  24  8170  ND  ND  25  8850  ND  ND  26  10800  ND  ND  Mean  3944  NA  NA  Median  2850  NA  NA  Range 1020-10800 NA NA * Abbreviations: ND, not detected, no chromatographic response (S/N < 3) was present at the appropriate retention time; S/N, signal to noise; S/N > 3, chromatographic response was present at the appropriate retention time with a S/N > 3 but failed ion ratio criteria; and NA, not applicable.
of morphine or of hydromorphone in humans. It would be expected that hydroxylation of hydromorphone to oxymorphone at the C-14 carbon position would be difficult because of the hindered nature of this carbon position and the relative inertness of a saturated carbon. Like hydromorphone, the C-14 carbon atom of morphine is a saturated carbon and is considered chemically unreactive (6) . In contrast, thebaine, which is olefinic in nature at the C-14 position, is readily hydroxylated (7) . In contrast to the negative findings for oxymorphone, hydromorphone was detected in each of the 34 patients (100%) undergoing high-dose morphine therapy. The mean (range) concentration of total hydromorphone in urine was 1575 ng/mL (338--4890 ng/mL). The ratio of hydromorphone to morphine ranged from 0.2% to 2.2%. Concentrations of hydromorphone were weakly correlated with morphine (r 2 = 0.36). These findings are similar to those of an earlier report of morphine metabolism to hydromorphone in pain patients undergoing chronic highdose morphine therapy (J). The ratio of hydromorphone to morphine in the earlier study ranged from 1.5% to 2.4%.
During chromatographic review of these data, evidence was also sought regarding the question of whether codeine might be a minor metabolite of morphine and whether hydrocodone might be a minor metabolite of hydromorphone. The formation of codeine from morphine was reported in older scientific literature (8) . Although these findings were later discounted (9,10), some confusion continues to exist as to whether codeine is a possible metabolite of morphine. Furthermore, older literature also has suggested that codeine contamination of pharmaceutical-grade morphine could account for the excretion of low concentrations of codeine in patients administered morphine (9) . Inspection of chromatograms from the high-dose morphine group revealed six examples in which codeine was measured at concentrations > LOQ (mean = 82 ng/mL, range 55-156 ng/mL) and two additional examples in which codeine was detected (> LOD). It should be noted that the analytical capabilities of the LC-MS-MS test system allowed detection of very low concentrations of codeine (> 25 ng/mL) in the presence of morphine at very high concentrations (> 100,000 ng/mL). The average amount of codeine detected in the six specimens relative to morphine was 0.04% (range --0.03-0.07%). Thus, it seems feasible that codeine contamination of pharmaceutical morphine at this level might explain the presence of codeine. Additional research will be needed to determine if these extremely minor amounts of codeine originated from pharmaceutical morphine or from morphine metabolism. Regarding whether hydrocodone might be a minor metabolite of hydromorphone, chromatographic review of the data from the high-dose hydromorphone patients revealed no evidence of hydrocodone at a detectable concentration (> LOD).
Two sources of error could have led to the inaccurate report that oxymorphone is a metabolite of morphine (3) . One source of error could have been problems with interfering peaks. In the current study, a minor peak was noted to elute near the retention time of oxymorphone. Careful comparison of relative retention times with deuterated oxymorphone was needed to distinguish the interference from oxymorphone. A second source of error could have been oxycodone use by patients. For example, if a pain patient is on high-dose morphine therapy and takes oxycodone for breakthrough pain, specimens collected shortly thereafter will test positive for oxycodone and oxymorphone, but late in the terminal elimination phase, specimens may be positive only for oxymorphone (4) . Thus, low concentrations of oxymorphone in combination with high concentrations of morphine could arise naturally from combined drug use and be mistaken for evidence that oxymorphone is a metabolite of morphine.
In conclusion, hydromorphone was demonstrated to be a minor metabolite of morphine as reported earlier (1), but no evidence was found that oxymorphone is a metabolite of morphine or hydromorphone. It is recognized that oxymorphone could have been present in some specimens below the LOD, but careful review of chromatograms produced no evidence of its presence. Study of additional patients is needed to support these findings. The current study clearly demonstrated that 60 patients receiving only high-dose morphine or high-dose hydromorphone therapy do not excrete oxymorphone in urine in detectable concentrations (> LOD). It is concluded, based on all available evidence in this study, that a positive urine test for oxymorphone can arise only from oxymorphone or oxycodone administration, and not from morphine or hydromorphone administration.
